Takeda Pharmaceutical Co. (NYSE:TAK) Shares Bought by Federated Hermes Inc.

Key Points

• Federated Hermes Inc. increased its stake in Takeda Pharmaceutical Co. by 24.6% during the 1st quarter, owning a total of 541,919 shares valued at approximately $8.06 million.
• Other institutional investors have also boosted their holdings significantly, including Soleus Capital Management, which raised its stake by 136.0% in the previous quarter.
• Takeda Pharmaceutical reported an EPS of $0.16 for the last quarter, missing expectations and generating revenue of $7.34 billion, below analysts' estimates of $8.02 billion.

Federated Hermes Inc. lifted its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 24.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 541,919 shares of the company's stock after purchasing an additional 106,885 shares during the quarter. Federated Hermes Inc.'s holdings in Takeda Pharmaceutical were worth $8,058,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Blair William & Co. IL raised its position in shares of Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after buying an additional 913 shares during the period. Vise Technologies Inc. raised its position in shares of Takeda Pharmaceutical by 3.1% in the 4th quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock worth $459,000 after buying an additional 1,026 shares during the period. Farther Finance Advisors LLC raised its position in shares of Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after buying an additional 1,045 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Takeda Pharmaceutical by 5.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock worth $319,000 after buying an additional 1,098 shares during the period. Finally, Allworth Financial LP raised its position in shares of Takeda Pharmaceutical by 12.7% in the 1st quarter. Allworth Financial LP now owns 10,797 shares of the company's stock worth $163,000 after buying an additional 1,215 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Up 0.5%

NYSE:TAK traded up $0.07 during mid-day trading on Wednesday, hitting $14.27. The company had a trading volume of 3,256,093 shares, compared to its average volume of 2,483,610. The business has a fifty day simple moving average of $14.84 and a 200-day simple moving average of $14.54. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.53. The firm has a market capitalization of $45.39 billion, a price-to-earnings ratio of 47.55 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.